Search engine for discovering works of Art, research articles, and books related to Art and Culture
ShareThis
Javascript must be enabled to continue!

Racial/Ethnic Disparities on the Risk of Second Malignant Neoplasm Among Hodgkin Lymphoma Survivors

View through CrossRef
BackgroundHodgkin lymphoma survivors are at risk for second malignant neoplasm (SMN). How race/ethnicity affects the risk remains unclear.MethodsThis retrospective cohort study included 22,415 patients diagnosed with primary Hodgkin lymphoma from January 1992 to December 2015 in 13 Surveillance, Epidemiology, and End Results-based registries and divided patients into four groups: non-Hispanic whites, non-Hispanic blacks, Hispanics, and Asian/others. Taking non-Hispanic whites as a reference, both the proportional subdistribution hazard (PSH) and the cause-specific hazard (CSH) methods were used to calculate the SMN hazard ratio for other racial/ethnic groups with and without considering the competing mortality risk.Results1,778 patients developed SMN with a median follow-up of 11.63 years. In the adjusted PSH model, Hispanic, Asian/others, and non-Hispanic black patients had 26% (PSH, 0.74; 95% CI, 0.63–0.87), 20% (PSH, 0.80; 95% CI, 0.64–1.01), and 12% (PSH, 0.88; 95% CI, 0.75–1.03) decreased overall SMN hazard, respectively. Moreover, the PSH method revealed the racial/ethnic difference in the SMN risk in the skin, the respiratory system, and the endocrine system. These hazards were slightly higher and different with the use of the CSH approach. In addition to the aforementioned overall SMN and subtypes, adjusted CSH analysis also revealed the racial/ethnic disparities in the risk of subsequent female breast cancer, digestive cancer, and non-Hodgkin lymphoma.ConclusionsThe subtype and SMN risk among Hodgkin lymphoma survivors varied by race/ethnicity. The use of CSH and PSH provides a dynamic view of racial/ethnic effects on SMN risk in Hodgkin lymphoma survivors.
Title: Racial/Ethnic Disparities on the Risk of Second Malignant Neoplasm Among Hodgkin Lymphoma Survivors
Description:
BackgroundHodgkin lymphoma survivors are at risk for second malignant neoplasm (SMN).
How race/ethnicity affects the risk remains unclear.
MethodsThis retrospective cohort study included 22,415 patients diagnosed with primary Hodgkin lymphoma from January 1992 to December 2015 in 13 Surveillance, Epidemiology, and End Results-based registries and divided patients into four groups: non-Hispanic whites, non-Hispanic blacks, Hispanics, and Asian/others.
Taking non-Hispanic whites as a reference, both the proportional subdistribution hazard (PSH) and the cause-specific hazard (CSH) methods were used to calculate the SMN hazard ratio for other racial/ethnic groups with and without considering the competing mortality risk.
Results1,778 patients developed SMN with a median follow-up of 11.
63 years.
In the adjusted PSH model, Hispanic, Asian/others, and non-Hispanic black patients had 26% (PSH, 0.
74; 95% CI, 0.
63–0.
87), 20% (PSH, 0.
80; 95% CI, 0.
64–1.
01), and 12% (PSH, 0.
88; 95% CI, 0.
75–1.
03) decreased overall SMN hazard, respectively.
Moreover, the PSH method revealed the racial/ethnic difference in the SMN risk in the skin, the respiratory system, and the endocrine system.
These hazards were slightly higher and different with the use of the CSH approach.
In addition to the aforementioned overall SMN and subtypes, adjusted CSH analysis also revealed the racial/ethnic disparities in the risk of subsequent female breast cancer, digestive cancer, and non-Hodgkin lymphoma.
ConclusionsThe subtype and SMN risk among Hodgkin lymphoma survivors varied by race/ethnicity.
The use of CSH and PSH provides a dynamic view of racial/ethnic effects on SMN risk in Hodgkin lymphoma survivors.

Related Results

Exploring the Association between Lymphoma and Inflammatory Bowel Disease in an Inner-City Academic Institution
Exploring the Association between Lymphoma and Inflammatory Bowel Disease in an Inner-City Academic Institution
Introduction: The incidence of lymphoma has been increasing over the past several decades, with data showing an estimated annual percentage change of 0.56%. There...
Primary Thyroid Non-Hodgkin B-Cell Lymphoma: A Case Series
Primary Thyroid Non-Hodgkin B-Cell Lymphoma: A Case Series
Abstract Introduction Non-Hodgkin lymphoma (NHL) of the thyroid, a rare malignancy linked to autoimmune disorders, is poorly understood in terms of its pathogenesis and treatment o...
Lymphomas
Lymphomas
Lymphoma is the fifth most common type of cancer in the United States, with 74,490 new cases estimated in 2009. Approximately 15% of patients with lymphoma have Hodgkin lymphoma; t...
Lymphomas
Lymphomas
Lymphoma is the fifth most common type of cancer in the United States, with 74,490 new cases estimated in 2009. Approximately 15% of patients with lymphoma have Hodgkin lymphoma; t...
Liệu pháp điều trị trúng đích trong u lympho không Hodgkin
Liệu pháp điều trị trúng đích trong u lympho không Hodgkin
U lympho là bệnh lý ác tính dòng lympho thường gặp nhất trong huyết học, bao gồm u lympho Hodgkin và u lympho không Hodgkin. Trong đó, u lympho không Hodgkin chiếm đa số (80 - 85%)...
Clinicopathological Features of Indeterminate Thyroid Nodules: A Single-center Cross-sectional Study
Clinicopathological Features of Indeterminate Thyroid Nodules: A Single-center Cross-sectional Study
Abstract Introduction Due to indeterminate cytology, Bethesda III is the most controversial category within the Bethesda System for Reporting Thyroid Cytopathology. This study exam...
Macrophages and Mast Cells Infiltration Are Biomarkers of Primary Refractory Hodgkin's Lymphoma
Macrophages and Mast Cells Infiltration Are Biomarkers of Primary Refractory Hodgkin's Lymphoma
Abstract Abstract 3881 Classical Hodgkin's lymphoma is a highly curable lymphoma and about 80% of patients can be cured with modern treatment strategi...

Back to Top